{"task_id": "648e9847f0655764", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 269/464)", "text": "HOICES (CONT\u2019D)\n258\nHerpes Simplex Virus Infection\n\n--- Page 280 ---\nHuman Immunodeficiency Virus\nNEJM 2005 353:16; MMWR 2009 58:RR-4;\nwww.aidsinfo.nih.gov/Guidelines/\nRISK FACTORS FOR HIV\nSEXUAL CONTACT\nhomosexual, heterosexual\nPARENTERAL\nIDU, transfusion, or unsafe needle\nuse in developing world, health workers\nMATERNAL FETAL\nin utero,\ndelivery,\nbreast\nfeeding\nACUTE HIV INFECTION\nSTRAINS\nHIV1 globally; HIV2 mainly in West\nAfrica\nSYMPTOMS\nacute febrile \u2018\u2018mononucleosis like\u2019\u2019\nillness, lymphadenopathy, pharyngitis, rash and\nheadache within 1\n6 weeks post exposure. Hema\ntologic (lymphopenia, thrombocytopenia) and liver\nenzyme abnormalities\nDIAGNOSIS\nELISA\nassay\n(sens\n\u0007100%,\nspc\n<100%) ! if positive, repeat ELISA ! if positive,\nWestern blot ! if indeterminate, repeat Western\nblot 4 6 weeks, 3 months, and 6 months later. If\nworrying about window period (2 6 weeks post\nexposure), may perform viral load testing\nBASIC WORKUP FOR THE NEWLY DIAGNOSED\n\u0002 HIV STATUS\nviral load, CD4 count, genotype\nantiretroviral drug resistance testing\n\u0002\nBASELINE\nCBCD, lytes, urea, Cr, AST, ALT, ALP,\nbilirubin, fasting lipid profile, amylase, lipase, CK,\nHLA B5701, bhCG, CXR, ECG\n\u0002\nCO-EXISTING/OPPORTUNISTIC INFECTIONS\nHAV ser\nology, HBV testing (HBsAg, HBsAb, HBcAb. If\nHBsAg or HBcAb positive, check HBV DNA as\nwell), HCV testing (HCV antibodies, if negative\nbut CD4 <200/mm3 and liver enzymes abnor\nmal, consider HCV RNA testing. If HCV positive,\nassess genotype \u0006 liver biopsy), Pap smear, anal\nscreening for HPV in gay men (no consensus\nyet), Chlamydia and gonorrhea screen, RPR\n(syphilis), TB skin test, toxoplasma serology,\nCMV serology\nNATURAL HISTORY OF HIV\nVIRAL LOAD\nrate of progression (speed of train).\nIndicates activity of viral replication. Critical measure\nof effect of antiretroviral therapy, once started\nCD4 COUNT\nprogress and stage of disease (dis\ntance to crash). Indicates relative health of immune\nsystem and risk of opportunistic complication\nFOLLOW UP\nviral load and CD4 count (usually 3 4\nmonth intervals, or q2 8weeks if change of HAART)\nAIDS\nCD4\n<200/mm3\nor\nany\nAIDS defining\ndiseases\n\u0002\nBACTERIAL\nMAC, TB, recurrent Salmonella sepsis\n\u0002\nVIRAL\nCMV retinitis, chronic HSV, PML\nNATURAL HISTORY OF HIV (CONT\u2019D)\n\u0002\nFUNGAL\nesophageal candidiasis, extrapulmonary\ncoccidioidomycosis, histoplasmosis or cryptococcosis\n\u0002\nPARASITIC\nPneumocystis jiroveci pneumonia (PJP),\ntoxoplasmosis,\nchronic\nCryptosporidiosis\nor\nisosporiasis\n\u0002\nHIV\nHIV encephalopathy, wasting syndrome\n\u0002\nNEOPLASMS\nKaposi\u2019s sarcoma, CNS lymphoma,\nnon Hodgkin\u2019s lymphoma, cervical carcinoma\nMAJOR CAUSES OF DEATH IN HIV PATIENTS ON\nHAART\nAIDS (30%), liver disease (14%), cardiovas\ncular disease (9%), non AIDS cancers (8%)\nCD4 COUNT AND PATHOLOGIES IN HIV PATIENTS\nCD4 count\n(/mm)3\n>500 200 500 100 200 <100\nKaposi sarcoma +\n+\n+\n+\nBacterial\n+\n+\n+\n+\nTB\n+\n+\n+\n+\nHSV\n+\n+\n+\n+\nCandida\n+\n+\n+\nCoccidioides\n+\n+\n+\nHistoplasma\n+\n+\n+\nPJP\n+\n+\nCryptococcus\n+\nToxoplasma\n+\nCMV\n+\nMAC\n+\nCNS lymphoma\n+\nCNS LESIONS IN HIV PATIENTS\nDIFFERENTIAL DIAGNOSIS\n\u0002\nBRAIN\nABSCESS\ntoxoplasma\n(CD4\n<100/mm3,\nusually multiple ring enhancing lesions), tubercu\nlosis (any CD4), Cryptococcus (CD4 <100/mm3),\nHistoplasma (CD4 <500/mm3), aspergillosis\n\u0002 CNS LYMPHOMA (CD4 <100/mm3)\n\u0002\nPROGRESSIVE MULT-IFOCAL LEUKOENCEPHALOPATHY (PML,\nCD4 <100/mm3)\nreactivation of JC virus, hypo\ndense white matter lesion\nDIAGNOSIS\nCBCD, lytes, urea, Cr, blood C&S, tox\noplasma IgG antibodies, EBV PCR, JC virus PCR, CT/MR\nhead, PET scan (CNS lymphoma has higher activity\nthan abscess), brain biopsy (if suspect CNS lym\nphoma). The combination of (1) multiple ring enhan\ncing lesions, (2) positive antitoxoplasmosis antibo\ndies, and (3) lack of toxoplasma prophylaxis in a HIV\npatient with CD4 count <100/mm3 has 90% PPV for\ndiagnosing toxoplasma\nTREATMENT\nOF\nTOXOPLASMOSIS\npyrimetha\nmine plus either sulfadiazine or clindamycin\nHuman Immunodeficiency Virus\n259", "text_length": 3882, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 269/464)", "type": "chunk", "chunk_index": 268, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.616801", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.617529", "status": "complete", "chunks_added": 2}